AstraZeneca Investor Day Presentation Deck

Forest plot of overall survival T300+D versus sorafenib in patient subgroups All patients Sex Age Region Viral etiology* ECOG PS* BCLC score MVI* EHS MVI and/or EHS PD-L1 status AFP Male Female <65 yr ≥65 yr Asia (except Japan) Rest of world (includes Japan) HBV HCV Nonviral 0 1 B C Yes No Yes No Yes No/no Positive+ Negative <400 ng/ml >400 ng/ml 0.25 40 Stratification factor. *Defined as tumor area positivity score 21%. T300+D, tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W. 0.5 T300+D vs sorafenib Favors T300+D 1 HR (95% CI) Favors sorafenib 2 HR (95% CI) 0.78 (0.66-0.92) 0.73 (0.61-0.88) 1.02 (0.67-1.56) 0.82 (0.65-1.04) 0.73 (0.58-0.93) 0.71 (0.54-0.92) 0.82 (0.66-1.02) 0.64 (0.48-0.86) 1.06 (0.76-1.49) 0.74 (0.57-0.95) 0.79 (0.63-0.98) 0.74 (0.57-0.95) 0.87 (0.57-1.33) 0.76 (0.63-0.91) 0.78 (0.57-1.07) 0.77 (0.63-0.93) 0.67 (0.53-0.84) 0.87 (0.67-1.11) 0.73 (0.59-0.89) 0.79 (0.58-1.06) 0.85 (0.65-1.11) 0.83 (0.65-1.05) 0.82 (0.63-1.05) 0.64 (0.45-0.91) B

View entire presentation